Navigation Links
Bioniche Reports Fiscal 2008 Second Quarter
Date:2/8/2008

ompany's education and awareness program focused on the dangers of E. coli O157:H7 and the importance of food and environmental safety.

Gross research and development expenses were $7.2 million for the six-month period ending December 31, 2007. This is unchanged from the same period in Fiscal 2007. The majority of these costs can be attributed to the ongoing Phase III clinical program with Urocidin(TM) in bladder cancer.

The basic net loss per share for the six-month period ending December 31, 2007 was ($0.13), compared to a net loss per share of ($0.14) recorded in the same period last year.

The balance sheet at December 31, 2007 shows:

- Total assets of $36.8 million, as compared to $41.5 million at

June 30, 2007.

- Working capital of $7.1 million, as compared to $14.4 million at

June 30, 2007.

- Shareholders' equity of $21.7 million, as compared to $29.1 million

at June 30, 2007.

- Cash and cash equivalents of $6.6 million, as compared to cash, cash

equivalents and short-term investments of $11.0 million at June 30,

2007.

- Unused revolving credit facilities of $1.6 million, as compared to

$1.8 million at the end of June 30, 2007.

"It is important to note that despite some going concern with our cash position, our commercial operations continue to perform nicely," said Patrick Montpetit, Chief Financial Officer of Bioniche Life Sciences Inc. "We are well positioned and committed to execute a strategic partnership transaction related to the financing of our bladder cancer therapy, Urocidin(TM), at the earliest opportunity."

The Company will discuss its second quarter results and other recent news during a:

Conference Call & Audio Web Cast

Tuesday, February 12, 2008

9:00 a.m. (Eastern)

To participate in the teleconference, call 4
'/>"/>

SOURCE Bioniche Life Sciences Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Bioniche Responds to Australian Equine Influenza Outbreak
2. Bioniche Receives $2 Million Government Grant For Market Development Related to its E. coli O157:H7 Cattle Vaccine
3. Bioniche Food Safety Vaccine Receives Global Top Honours in Industry Excellence Awards
4. Bioniche Receives Comment from USDA on a Field Trial for E. coli O157:H7 Cattle Vaccine
5. Media Advisory - Bioniche Discusses USDA Comment on E. coli O157:H7 Cattle Vaccine Field Trial
6. Bioniche to Present at Rodman & Renshaw 9th Annual Healthcare Conference
7. Bioniche Reports Fiscal 2008 First Quarter
8. Bioniche Receives $5 Million of Federal Government Support to Scale-up Vaccine Production in Ontario
9. Bioniche Amends Terms of Convertible Debt with Laurus Master Funds
10. USDA Agrees to Grant Conditional License to Bioniche for its E. coli O157:H7 Cattle Vaccine
11. New Study Reports High Injury Rates for Hotel Workers, Even Higher Rates for Women and Nonwhites
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/25/2014)... When head lice hits a home or school, ... get rid of it while keeping it from taking over ... have the solution right in their neighborhood: Lice Troopers ... provides full spectrum head lice screening and treatment services to ... Key Biscayne, Brickell, Coconut Grove, Kendall, Pinecrest and South Miami. ...
(Date:12/25/2014)... -- Overeating is common during the holidays, but there are ... says. "Don,t arrive at a party hungry. It may ... be attending a party, but deprivation leads to hunger, and ... Westchester Hospital in Mount Kisco, N.Y., said in a hospital ... day and even to have a snack before attending a ...
(Date:12/25/2014)... New York, New York (PRWEB) December 25, 2014 ... ) continue to move forward in a number ... Southern District of West Virginia, Bernstein Liebhard LLP reports. ... the Court is scheduled to convene a Joint Status ... 2015, at 10:00 a.m. Parties have been directed to ...
(Date:12/25/2014)... (PRWEB) December 25, 2014 Each year ... and 2 million hospital admissions across the nation (according ... ). The CDC’s National Hospital Ambulatory Medical Care ... a survey conducted in 2010. They estimated that there ... that resulted in a primary diagnosis of broken bone ...
(Date:12/24/2014)... 25, 2014 Epigenetics finds applications in ... including oncology, drug discovery, developmental biology, and research for ... one of the most widely used techniques for the ... the prevalence of cancer is rapidly growing worldwide. In ... million cancer deaths, and 32.6 million people living with ...
Breaking Medicine News(10 mins):Health News:Coral Gables Florida Gets Ready to Be Lice-Free with Lice Troopers 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 2Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 3Health News:Federal Court Overseeing Thousands of Transvaginal Mesh Lawsuits Set to Convene Joint Status Conference for All Litigations, Bernstein Liebhard LLP Reports 4Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 2Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 3Health News:Every Year Four Million Emergency Department Visits Result from Accidents Involving Bone Trauma 4Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 2Health News:Global Epigenetics Market Was Valued at $413.24 Million in 2014 - New Research Report by MarketsandMarkets 3
... 12 million people in the United States are cancer survivors. ... annually than the care of people who have never had ... are treated for and survive cancer are susceptible to later ... per year. People are considered cancer survivors from the moment ...
... Multiple Sclerosis sufferers emotional support through group therapy sessions ... NHS almost 500 per patient, a study at The ... planning a larger multi-centre study into the issue to ... MS services currently provided by the NHS. The ...
... identify patients who will benefit from a potentially toxic second ... of cure in select patients with head and neck cancer. ... of the American Cancer Society, the findings could help guide ... Radiation is often used to treat patients with head and ...
... the brain activity of teens, recorded while they are listening ... songs. "We have scientifically demonstrated that you can, to ... predict cultural popularity," says Gregory Berns, a neuroeconomist and director ... Consumer Psychology is publishing the results of the study, ...
... June 10 (HealthDay News) -- The debate over whether or not ... study finds a small risk among people who are heavy cell ... Dr. Otis Brawley, chief medical officer of the American Cancer ... "the study is not conclusive that cell phones cause brain tumors." ...
... , SATURDAY, June 11 (HealthDay News) -- Baseline concussion ... some cases, an expert warns. Baseline concussion testing provides ... reaction time, working memory and attention span. Athletes who suffer ... large decrease in the score, they are typically banned from ...
Cached Medicine News:Health News:Cancer survivors spend more on health care 2Health News:Group therapy helps MS sufferers cope with depression, study finds 2Health News:Group therapy helps MS sufferers cope with depression, study finds 3Health News:Certain head and neck cancer patients benefit from second round of treatment 2Health News:Teen brain data may predict pop song success, Emory study finds 2Health News:Teen brain data may predict pop song success, Emory study finds 3Health News:Heavy Cell Phone Use Might Raise Risk of Brain Tumors 2Health News:Heavy Cell Phone Use Might Raise Risk of Brain Tumors 3Health News:Validity of Baseline Concussion Tests Questioned 2
(Date:12/22/2014)... -- ConvaTec, a privately-held medical products and technologies company, today ... Executive Officer of the company, effective December 22, 2014. ... "The Board of Directors of ConvaTec thanks Mr. Berger ... three years," said Magnus Lundberg , the Chairman ... the company is well positioned for the future."  The ...
(Date:12/22/2014)... Mass , Dec. 22, 2014 /PRNewswire/ -- RXi ... biotechnology company focused on discovering, developing and commercializing ... RNA-targeted technologies, today issued the following open letter ... Cauwenbergh , Dr. Med. Sc. Dear ... days a number of inaccurate statements posted on ...
(Date:12/22/2014)... 22, 2014  Pfenex Inc. (NYSE MKT: PFNX) today ... has been filed and is now open and that ... Department of Health and Human Services (HHS), through the ... "We are extremely pleased to have the IND now ... a significant milestone in our company,s partnership with BARDA ...
Breaking Medicine Technology:ConvaTec Names Paul Moraviec Interim CEO Effective December 22, 2014 2RXi Pharmaceuticals Issues Open Letter to Shareholders 2RXi Pharmaceuticals Issues Open Letter to Shareholders 3RXi Pharmaceuticals Issues Open Letter to Shareholders 4RXi Pharmaceuticals Issues Open Letter to Shareholders 5RXi Pharmaceuticals Issues Open Letter to Shareholders 6Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 2Pfenex Announces Active IND and Additional BARDA Funding for Recombinant Anthrax Vaccine Program, Px563L 3
... Orexigen® Therapeutics, Inc. (Nasdaq: OREX ), ... today announced the appointment of Wendy Dixon , ... 30 years of pharmaceutical development and commercial experience to ... product launches and portfolio evaluation in cardiometabolic and primary ...
... , MADRID , April 21 PharmaMar, ... with marine-based anti-tumor drugs Yondelis(R), Zalypsis(R) and Irvalec(R) at the American Association ... from April 17-21 . , ... The AACR meeting is the leading convention on cancer research, ...
Cached Medicine Technology:Orexigen(R) Therapeutics Appoints Wendy Dixon, Ph.D. to Board of Directors 2Orexigen(R) Therapeutics Appoints Wendy Dixon, Ph.D. to Board of Directors 3PharmaMar Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention 2PharmaMar Presents New Clinical Trials With Three Marine-Based Drugs at the American Association for Cancer Research Convention 3
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: